个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ ESCI

作者：
Xinyue Chen[1] * ; Qianguo Mao[2] * ; Yao Xie[3] * ; Xiaoguang Dou[4] ; Qing Xie[5] ; Jifang Sheng[6] ; Zhiliang Gao[7] ; Xiaoling Zhou[8] ; Yingxia Liu[9] ; Huanwei Zheng[10] ; Shuqin Zhang[11] ; Shibo Li[12] ; Fusheng Zhu[13] ; Yuqin Xu[14] ; Mingxiang Zhang[15] ; Yaoren Hu[16] ; Xiaoping Chen[17] ; Yan Huang[18] ; Hong Ren[19,*1] ; Jidong Jia[20,*2] ;
机构： [1]International Medicine Ward, Beijing YouAn Hospital, Capital Medical University, Beijing, China [2]Department of Infectious Diseases, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China [3]Department of Liver Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China [4]Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China [5]Department of Infectious Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [6]Department of Infectious Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China [7]Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China [8]Department of Gastroenterology, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi, China [9]Department of Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, Guangdong, China [10]Department of Infectious Diseases, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China [11]Department of Infectious Diseases, Hepatology Hospital of Jilin Province, Changchun, Jilin, China [12]Department of Infectious Diseases, Zhoushan Hospital of Zhejiang Province, Zhoushan, Zhejiang, China [13]Department of Infectious Diseases, General Hospital of Dagang Oilfield, Tianjin, China [14]Department of Infectious Diseases, The 211 Hospital of People’s Liberation Army, Harbin, Heilongjiang, China [15]Department of Integrated Traditional and Western Medicine on Liver Diseases, The Sixth People’s Hospital of Shenyang, Shenyang, Liaoning, China [16]Department of Liver Disease, Ningbo No. 2 Hospital of Zhejiang Province, Ningbo, Zhejiang, China [17]Department of Infectious Diseases, Guangdong General Hospital, Guangzhou, Guangdong, China [18]Department of Medical Science, Shanghai Roche Pharmaceuticals Ltd., Shanghai, China [19]Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China [20]Department of Liver Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China
出处：
DOI： 10.14218/JCTH.2019.00016
ISSN：

关键词： Chronic hepatitis B Prospective studies Observational study Interferon alpha

摘要：
Background and Aims: Data are limited on the use of pegylated-interferon alpha-2a (peg-IFN alpha) in Chinese patients with chronic hepatitis B virus (HBV) infection (CHB). We evaluated the effectiveness and safety of peg-IFNa in Chinese patients with hepatitis B envelope antigen-negative CHB in routine clinical practice. Methods: In this prospective, multi-center, observational, non-interventional cohort study, patients were assessed for up to 1 year after peg-IFNa treatment cessation. Treating physicians established the dosing and treatment duration according to Chinese clinical practice. Effectiveness of peg-IFNa treatment was measured by the percentage of: patients with HBV DNA <2000 IU/mL and loss of hepatitis B surface antigen (commonly known as HBsAg); HBV DNA level at end of treatment (EOT), and 6 months and 1 year posttreatment; and time course change in quantitative HBV DNA and HBsAg. Results: At EOT, 6 months posttreatment, and 1 year posttreatment, the percentage of patients with HBV DNA <2000 IU/mL was 90.0%, 81.8%, and 82.2%, and that of patients with HBsAg loss was 6.5%, 9.4%, and 9.5%, respectively. The HBV DNA level decreased from 5.61 log IU/mL at baseline to 2.48 log IU/mL at EOT and 2.67 log IU/mL at 1 year posttreatment. The HBsAg level decreased from 3.08 log IU/mL at baseline to 2.24 log IU/mL at EOT and 2.10 log IU/mL at 1 year posttreatment. The incidence of adverse events was 52.0%. Conclusions: Peg-IFN alpha has the potential to provide functional cure (HBsAg loss) for CHB and is well tolerated in hepatitis B envelope antigen-negative CHB patients in routine clinical practice in China.

基金：
The study was funded by Shanghai Roche Pharmaceuticals Ltd.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
无
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 胃肠肝病学
JCR分区：
出版当年[2017]版：
无
最新[2023]版：
Q2 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版]

第一作者：
第一作者机构： [1]International Medicine Ward, Beijing YouAn Hospital, Capital Medical University, Beijing, China
共同第一作者：
通讯作者：
通讯机构： [19]Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China [20]Department of Liver Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China [*1]Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, No. 76, Linjiang Road, Yuzhong District, Chongqing 400010, China. [*2]Department of Liver Disease, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong’an Road, Xicheng District, Beijing 100069, China.
推荐引用方式(GB/T 7714)：
Xinyue Chen,Qianguo Mao,Yao Xie,et al.A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a[J].JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY.2019,7(3):249-257.doi:10.14218/JCTH.2019.00016.
APA：
Xinyue Chen,Qianguo Mao,Yao Xie,Xiaoguang Dou,Qing Xie...&Jidong Jia.(2019).A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a.JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY,7,(3)
MLA：
Xinyue Chen,et al."A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a".JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY 7..3(2019):249-257

相关文献

[1]Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients [2]Rare inborn errors associated with chronic hepatitis B virus infection [3]慢性乙型肝炎中医诊疗方案的优化研究 [4]Effect of seasonal variation on the clinical course of chronic hepatitis B. [5]High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. [6]慢性乙型肝炎患者病毒基因组与乙型肝炎病毒e抗原、肝功能关系分析 [7]A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. [8]Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience [9]Yinchenhao decoction for chronic hepatitis B: Protocol for a systematic review and meta-analysis. [10]Traditional Chinese medicine syndromes of chronic hepatitis B with precore mutant.

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号